Mosi Bennett
Advanced Heart Failure and Transplant Cardiology · Minneapolis, MNNPI 1396881181
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $121,688 of the $182,844 with a category attached, or 66.6%. Abbott accounts for 60.0% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $97,001, more than ten times the $8,979 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $605.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$110K
- Endotronix, Inc.$36K
- Medtronic$13K
- Abiomed$12K
- Cvrx, Inc.$12K
- Impulse Dynamics (USA) Inc.$310
- plus $470 from 7 others
Across 106 payments — averaging $6279.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$293K
- Abbott$241K
- Ionis Pharmaceuticals, Inc.$49K
- Bayer$31K
- AstraZeneca$29K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
- plus $5K from 1 others
What the payments were for
- Consulting fees$121,68867%
- Speaking & faculty fees$29,82916%
- Travel & lodging$21,03812%
- Food & beverage$10,2726%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 229 | $109,725 |
| Endotronix, Inc. | 9 | $36,475 |
| Medtronic(2 entities) | 14 | $12,608 |
| Abiomed | 21 | $11,722 |
| Cvrx, Inc. | 18 | $11,533 |
| Impulse Dynamics (USA) Inc. | 2 | $310 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $145 |
| ZOLL Respicardia, Inc. | 2 | $127 |
| Itamar Medical Inc | 1 | $121 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Merck | 1 | $18 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$54,903
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$31,580
- CardioMEMS HF System$19,359
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$16,197
- Barostim Neo System$11,327
- CORDELLA PULMONARY ARTERY PRESSURE SENSOR$4,750
- Ensite Cardiac Mapping System$3,600
- Gallant CRT-D$3,500
- HeartMate$2,588
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$1,899
- HeartMate 3 Left Ventricular Dev$1,350
- HeartWare HVAD$1,350
- Impella$639
- OPTIMIZER$621
- Cardiovascular- Research only$612
- ENSITE$278
- LifeVest$123
- WatchPATONE$121
- remede System$112
- Micra$109
How this compares
$182,844 in reported general payments places this provider in the 95th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.
See all advanced heart failure and transplant cardiology providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 41 | $917,677 |
| EntrestoSacubitril/Valsartan | 464 | $426,923 |
| FarxigaDapagliflozin Propanediol | 209 | $167,548 |
| JardianceEmpagliflozin | 85 | $85,112 |
| EliquisApixaban | 75 | $68,128 |
| XareltoRivaroxaban | 34 | $49,672 |
| OzempicSemaglutide | 13 | $12,659 |
| Torsemide | 137 | $6,687 |
| Potassium Chloride | 110 | $6,150 |
| Tacrolimus | 11 | $4,184 |
| Bumetanide | 51 | $3,920 |
| Spironolactone | 293 | $2,810 |
| Carvedilol | 225 | $2,764 |
| Metoprolol Succinate | 128 | $2,659 |
| Mycophenolate Mofetil | 21 | $2,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $426,923464 claims |
| Boehringer IngelheimJardiance | $22 | $85,11285 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.
Other advanced heart failure and transplant cardiology in Minneapolis
- Valmiki MaharajMinneapolis$38K
- Jessica SchultzMinneapolis$8K
- Michael SamaraMinneapolis$168
- Barry BorlaugRochester$173K
- Robert FrantzRochester$141K
- Terrie-Ann BenjaminSaint Paul$107K
- Omar AbouezzeddineRochester$10K
- Swaiman SinghRochester$9K
- Dipan UppalRochester$4K
- Naveen PereiraRochester$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.